Normal amniotic fluid proteome variation by iTRAQ approach

Abstract

Amniotic fluid (AF) contains large amounts of proteins produced by amnion epithelial cells, fetal tissues, fetal excretions and placental tissues; thus, it is an important potential source of biomarkers for identifying fetal pathologies. In this study, a pooled AF sample from 7 healthy volunteers was used to analyze inter-individual variations with iTRAQ method. The inter-individual variation analysis of 7 individual AF samples showed that the median inter-individual CV (Coefficient of variation) was 0.22. iBAQ quantification analysis revealed that the inter-individual variations were not correlated with protein abundance. GO analysis indicated that intracellular proteins tended to have higher CVs, and extracellular proteins tended to have lower CVs.

Each individual AF sample was used for the inter-individual variation analysis with RP-RP LC-MS/MS and iTRAQ methods.

Amniotic fluid (AF) obtained from volunteers of similar ages (28 to 30 years with a median age of 29 years) in the 16th–20th weeks of pregnancy.

Protocol Description
Clinical materials

Amniotic fluid (AF) samples were obtained by amniocentesis from women at 16–20 weeks of gestation undergoing prenatal diagnosis. Considering the interference of various factors, we screened eligible volunteers of similar ages (28 to 30 years with a median age of 29 years) in the 16th–20th weeks of pregnancy.

Sample preparation

The 7 AF samples were precipitated overnight using 3 times the volume of ethanol at 4 °C. Then, after centrifugation at 10000×g for 30 min, the pellets were resuspended in lysis buffer (7M urea, 2M thiourea, 0.1M DTT, and 5mM Tris). The protein concentration of each sample was determined by spectrophotometry based on the Bradford method. Two hundred micrograms of each individual AF sample was used for analyzing the inter-individual variation. The 7 individual samples were digested using a filter-aided sample preparation (FASP) method. Protein samples (200 μg) were reduced with 20mM DTT at 95 °C for 5 min and then carboxyamidomethylated with 50mM IAM at room temperature in the dark for 45 min. Trypsin (4 μg) in 25mM NH4HCO3 was added to each protein sample for digestion overnight at 37 °C. After digestion, the resulting peptides were desalted on a Waters Oasis C18 solid-phase extraction column and lyophilized for HPLC separation.

iTRAQ Or TMT labeling

The 7 individual resulting peptides were pooled into one control sample with the same amounts. Then, the control and 7 individual peptides were labeled with an 8-plex iTRAQ reagent as follows: 113, 114, 115, 116, 117, 118, 119, and 121.

HPLC

The labeled samples were fractioned with a high-pH RPLC column from Waters (4.6 mm×250 mm, Xbridge C18, 3 μm). The samples were loaded onto the column in buffer A1 (H2O, pH=10). The eluted gradient was 5–30% buffer B1 (90% ACN, pH=10, flow rate=1 mL/min) for 60 min. The eluted peptides were collected at a rate of one fraction per minute. After lyophilization the 60 fractions were resuspended in 0.1% formic acid and concatenated into 20 fractions by combining fractions 1, 21, 41, etc.

LC/MS/MS

Each fraction was analyzed using an RP C18 self-packing capillary LC column (75 μm×100mm, 3 μm). The eluted gradient was 5–30% buffer B2 (0.1% formic acid, 99.9% ACN; flow rate, 0.3 μL/min) for 40min. A TripleTOF 5600 mass spectrometer was used to analyze the eluted peptides from LC. The MS data were acquired in high sensitivity mode using the following parameters: 30 data-dependent MS/MS scans per full scan; full scans were acquired at a resolution of 40,000 and MS/MS scans at 20,000; rolling collision energy, charge state screening (including precursors with +2–+4 charge state) and dynamic exclusion (exclusion duration 15 s); the MS/MS scan range was 100–1800m/z;and thescan time was 100 ms.

Data processing

Scaffold Q+ (version Scaffold_4.7.3, Proteome Software Inc., Portland, OR) was used to perform the Label-Based Quantification (e.g., iTRAQ, TMT, SILAC) for peptide and protein identification.